Clinical and Translational Radiation Oncology (Nov 2020)
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
- Gerard M. Walls,
- Jamie B. Oughton,
- Anthony J. Chalmers,
- Sarah Brown,
- Fiona Collinson,
- Martin D. Forster,
- Kevin N. Franks,
- Alexandra Gilbert,
- Gerard G. Hanna,
- Nicola Hannaway,
- Stephen Harrow,
- Tom Haswell,
- Crispin T. Hiley,
- Samantha Hinsley,
- Matthew Krebs,
- Geraldine Murden,
- Rachel Phillip,
- Anderson J. Ryan,
- Ahmed Salem,
- David Sebag-Montefoire,
- Paul Shaw,
- Chris J. Twelves,
- Katrina Walker,
- Robin J. Young,
- Corinne Faivre-Finn,
- Alastair Greystoke
Affiliations
- Gerard M. Walls
- Patrick G Johnston Centre for Cancer Research, Queen’s University Belfast, Northern Ireland, UK; Corresponding author.
- Jamie B. Oughton
- Leeds Institute of Clinical Trials Research, University of Leeds, England, UK
- Anthony J. Chalmers
- Institute of Cancer Sciences, University of Glasgow, Scotland, UK
- Sarah Brown
- Leeds Institute of Clinical Trials Research, University of Leeds, England, UK
- Fiona Collinson
- Leeds Institute of Clinical Trials Research, University of Leeds, England, UK
- Martin D. Forster
- Department of Oncology, UCL Cancer Institute, England, UK
- Kevin N. Franks
- St James’ Institute of Oncology, University of Leeds, England, UK
- Alexandra Gilbert
- St James’ Institute of Oncology, University of Leeds, England, UK
- Gerard G. Hanna
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia
- Nicola Hannaway
- Newcastle University, Newcastle upon Tyne, England, UK
- Stephen Harrow
- The Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK
- Tom Haswell
- Patient and Public Involvement Advocacy, UK
- Crispin T. Hiley
- Department of Oncology, UCL Cancer Institute, England, UK
- Samantha Hinsley
- Leeds Institute of Clinical Trials Research, University of Leeds, England, UK; Institute of Cancer Sciences, University of Glasgow, Scotland, UK
- Matthew Krebs
- Faculty of Biology, Medicine and Health, University of Manchester, England, UK
- Geraldine Murden
- Leeds Institute of Clinical Trials Research, University of Leeds, England, UK
- Rachel Phillip
- Leeds Institute of Clinical Trials Research, University of Leeds, England, UK
- Anderson J. Ryan
- Oxford Institute for Radiation Oncology, University of Oxford, Oxford, England, UK
- Ahmed Salem
- The Christie NHS Foundation Trust/University of Manchester, Manchester, England, UK
- David Sebag-Montefoire
- St James’ Institute of Oncology, University of Leeds, England, UK
- Paul Shaw
- Velindre University NHS Trust, Cardiff, Wales, UK
- Chris J. Twelves
- St James’ Institute of Oncology, University of Leeds, England, UK
- Katrina Walker
- Leeds Institute of Clinical Trials Research, University of Leeds, England, UK
- Robin J. Young
- Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, England, UK
- Corinne Faivre-Finn
- Oxford Institute for Radiation Oncology, University of Oxford, Oxford, England, UK
- Alastair Greystoke
- Newcastle University, Newcastle upon Tyne, England, UK
- Journal volume & issue
-
Vol. 25
pp. 61 – 66
Abstract
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.
